Brexit Could Mean Big Changes for EMA

Overview


Stephan Rau and Emmanuelle Trombe, who represent pharmaceutical, medical device, biotech and healthcare companies, said that “it is not clear yet whether (and if so, how and when) Brexit will really take place.” Still, they added that “the uncertainty created by the Brexit vote is generally bad for the economy but might be particularly tough for the biotech industry, given its financing needs and its risk profile highly dependent on financial markets making it very volatile.”